Fibroblast growth factor receptor

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090

Monday, February 22, 2021 - 6:40am

In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.

Key Points: 
  • In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.
  • Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
  • et al., "Biliary tract cancer registry in Japan from 2008 to 2013", J Hepatobiliary Pancreat Sci., 2016, 23, 149-157.
  • (6) Arai Y. et al., "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma", Hepatology, 2014, 59, 1427-1434.

Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers

Friday, January 15, 2021 - 11:55am

Stomatitis (31.6% vs 13.0%) and elevated transaminases (34.2% vs 19.5%) were also more common in the bemarituzumab arm.

Key Points: 
  • Stomatitis (31.6% vs 13.0%) and elevated transaminases (34.2% vs 19.5%) were also more common in the bemarituzumab arm.
  • Ocular events are common in therapies targeting FGFR and were also reported in the FIGHT trial.
  • To participate in the conference call, please dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID: 2063209.
  • Bemarituzumab is being developed in gastric and GEJ cancer as a targeted therapy for tumors that overexpress FGFR2b.

Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020

Monday, October 26, 2020 - 6:15am

In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).

Key Points: 
  • In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).
  • The presented data from several preclinical models demonstrate that derazantinib has an anti-angiogenic effect, which may contribute to its overall anti-tumor activity in FGFR-driven cancers.
  • Dr. Laurenz Kellenberger, Chief Scientific Officer, said: Our development strategy for derazantinib is focused on strengthening the evidence for its differentiation versus other FGFR inhibitors.
  • The preclinical data on derazantinibs anti-angiogenic activity presented at the conference show that it may provide additional activity on top of its established primary anti-tumor effects in FGFR-positive solid tumors.

Basilea reports data from poster presentations at ESMO Virtual Congress 2020

Tuesday, September 22, 2020 - 6:15am

Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.
  • In addition, gastric and lung cancer models showed the strongest correlation of FGFR1-3 expression versus the anticancer activity of derazantinib.
  • The results support the planned clinical investigation of derazantinib in gastric cancer as its next indication.
  • Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China

Thursday, September 3, 2020 - 7:04am

In normal physiology, FGF/FGFR signaling is involved in embryonic development (organogenesis and morphogenesis), tissue repair, angiogenesis, neuroendocrine and metabolism homeostasis.

Key Points: 
  • In normal physiology, FGF/FGFR signaling is involved in embryonic development (organogenesis and morphogenesis), tissue repair, angiogenesis, neuroendocrine and metabolism homeostasis.
  • Enrollment has been completed for the dose escalation of the Phase I study of HMPL-453 in China (clinicaltrials.gov identifier NCT03160833 ).
  • Enrollment of a Phase II study is ongoing in patients with advanced malignant mesothelioma in China (clinicaltrials.gov identifier NCT04290325 ).
  • For further discussion of these and other risks, see Chi-Meds filings with the U.S. Securities and Exchange Commission and on AIM.

Basilea announces data presentations at ESMO Virtual Congress 2020

Tuesday, July 28, 2020 - 6:15am

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that three abstracts featuring preclinical and clinical data on its fibroblast growth factor receptor (FGFR) kinase inhibitor derazantinib and its tumor checkpoint controller lisavanbulin are going to be presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which is taking place from 19-21 September, 2020.

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that three abstracts featuring preclinical and clinical data on its fibroblast growth factor receptor (FGFR) kinase inhibitor derazantinib and its tumor checkpoint controller lisavanbulin are going to be presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which is taking place from 19-21 September, 2020.
  • Dr. Marc Engelhardt, Chief Medical Officer, said: The preclinical derazantinib data may provide an explanation for differences in reported adverse event profiles between various FGFR kinase inhibitors.
  • He continued: We are also pleased that the full data from the phase 1 study with oral lisavanbulin in patients with recurrent glioblastoma will be presented at ESMO.
  • Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

RIBOMIC Announces Dosing of First Subject in RBM-007 Phase 1 Clinical Trial for Achondroplasia

Wednesday, July 15, 2020 - 2:30pm

Achondroplasia has no known cure, and is designated as an intractable disease by the Ministry of Health, Labour and Welfare in Japan.

Key Points: 
  • Achondroplasia has no known cure, and is designated as an intractable disease by the Ministry of Health, Labour and Welfare in Japan.
  • This disease results mainly from a genetic variant in FGFR3 (fibroblast growth factor type 3 receptor).
  • Achondroplasia occurs in a frequency of 1 in approximately 25,000 normal live births and is estimated to affect approximately 250,000 people worldwide.
  • "RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia

Wednesday, July 15, 2020 - 12:30pm

Additionally, infigratinib is being studied as a once-daily dose taken orally, which is an important factor for administration of therapies to children with achondroplasia.

Key Points: 
  • Additionally, infigratinib is being studied as a once-daily dose taken orally, which is an important factor for administration of therapies to children with achondroplasia.
  • Our hope is that a daily, oral dose of infigratinib, which directly targets FGFR3, can provide health benefits for children with achondroplasia.
  • The PROPEL 2 trial is a Phase 2 dose escalation and dose expansion trial and the first clinical trial to study infigratinib at low doses in children with achondroplasia.
  • QED Therapeutics , an affiliate of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven diseases.

Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020

Thursday, June 4, 2020 - 1:00pm

PRINCETON, N.J., June 4, 2020 /PRNewswire/ --Taiho Oncology, Inc. today announced that preclinical data for futibatinib (TAS-120) will be presented online during the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 from June 22-24.

Key Points: 
  • PRINCETON, N.J., June 4, 2020 /PRNewswire/ --Taiho Oncology, Inc. today announced that preclinical data for futibatinib (TAS-120) will be presented online during the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 from June 22-24.
  • Key presentations include:
    Futibatinib (TAS-120) plus chemotherapy demonstrated a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models (Abstract 564).
  • Results will be shared online as a poster presentation on June 22, 2020.
  • The abstract for this presentation is available on the AACR website: https://www.abstractsonline.com/pp8/#!/9045/presentation/2469
    Synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors (Abstract 659).

GeneCentric Therapeutics to Present New Analyses of Molecular Characterization and Prediction of Treatment Response in Patients with Muscle Invasive Bladder Cancer (MIBC)

Thursday, February 13, 2020 - 2:30pm

GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.

Key Points: 
  • GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.
  • The data are derived from GeneCentrics expertise in the identification of RNA-based Predictive Response Signatures and through collaborations with researchers at leading institutions and pharmaceutical companies.
  • The predictive value of fibroblast growth factor (FGFR) alterations on the treatment outcome of MIBC patients treated with immune checkpoint blockade (Anti-PD-L1/Anti-PD-1) was evaluated in the current analysis.
  • Details of the presentations are as follows:
    GeneCentric Therapeutics, Inc., based in Research Triangle Park, N.C., is an RNA-based genomic solutions provider.